176 related articles for article (PubMed ID: 7504129)
1. Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
Jacob BG; Richter WO; Schwandt P
J Cardiovasc Pharmacol; 1993 Sep; 22(3):396-400. PubMed ID: 7504129
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Jacob BG; Möhrle W; Richter WO; Schwandt P
Eur J Clin Pharmacol; 1992; 42(4):353-8. PubMed ID: 1516599
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
Richter WO; Jacob BG; Schwandt P
Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Strauss WE; Lapsley D; Gaziano JM
Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
[TBL] [Abstract][Full Text] [Related]
6. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years.
Simons LA; Nestel PJ; Clifton P; Janus ED; Simons J; Parfitt A
Med J Aust; 1992 Nov; 157(9):584-9. PubMed ID: 1406416
[TBL] [Abstract][Full Text] [Related]
7. A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
Ozsener S; Sendag F; Koc T; Terek MC; Oztekin K; Bilgin O
J Obstet Gynaecol Res; 2001 Dec; 27(6):353-8. PubMed ID: 11794823
[TBL] [Abstract][Full Text] [Related]
8. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
9. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
Pan HY; DeVault AR; Swites BJ; Whigan D; Ivashkiv E; Willard DA; Brescia D
Clin Pharmacol Ther; 1990 Aug; 48(2):201-7. PubMed ID: 2116260
[TBL] [Abstract][Full Text] [Related]
11. [Pravastatin, cholestyramine and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open randomized comparative study].
Ditschuneit HH; Dreyer M; Dammann HG; Ditschuneit H
Med Klin (Munich); 1991 Mar; 86(3):142-8. PubMed ID: 1903497
[TBL] [Abstract][Full Text] [Related]
12. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
13. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
Kostis JB; Rosen RC; Wilson AC
J Clin Pharmacol; 1994 Oct; 34(10):989-96. PubMed ID: 7836550
[TBL] [Abstract][Full Text] [Related]
15. Comparison between low-dose simvastatin and cholestyramine in moderately severe hypercholesterolemia.
Deslypere JP
Acta Cardiol; 1989; 44(5):379-88. PubMed ID: 2690545
[TBL] [Abstract][Full Text] [Related]
16. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care.
Eriksson M; Hådell K; Holme I; Walldius G; Kjellström T
J Intern Med; 1998 May; 243(5):373-80. PubMed ID: 9651560
[TBL] [Abstract][Full Text] [Related]
17. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia.
Leren TP; Hjermann I; Berg K; Leren P; Foss OP; Viksmoen L
Atherosclerosis; 1988 Oct; 73(2-3):135-41. PubMed ID: 3056429
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Davignon J; Hanefeld M; Nakaya N; Hunninghake DB; Insull W; Ose L
Am J Cardiol; 1998 Aug; 82(4B):32J-39J. PubMed ID: 9737644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
